Nanjing Vazyme Biotech Co Ltd (688105) — Working Capital to Net Assets Ratio
Nanjing Vazyme Biotech Co Ltd (688105) has a Working Capital to Net Assets ratio of 70.9% as of March 2026. Working capital of CN¥2.69 Billion (current assets of CN¥3.81 Billion minus current liabilities of CN¥1.13 Billion) is measured against net assets of CN¥3.79 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See Nanjing Vazyme Biotech Co Ltd balance sheet independence to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Nanjing Vazyme Biotech Co Ltd Working Capital to Net Assets (2017–2025)
This chart shows how Nanjing Vazyme Biotech Co Ltd's Working Capital to Net Assets ratio has evolved across 9 annual periods from 2017 to 2025. As of March 2026, the ratio stands at 70.9%, reflecting working capital of CN¥2.69 Billion against net assets of CN¥3.79 Billion CNY. Check 688105 goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for Nanjing Vazyme Biotech Co Ltd (2017–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Nanjing Vazyme Biotech Co Ltd from 2017 to 2025, covering 9 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see 688105 company net worth.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 70.3% | CN¥2.67 Billion | CN¥3.79 Billion | CN¥3.71 Billion | CN¥1.04 Billion | ▲ +2.7 pp |
| 2024 | 67.7% | CN¥2.67 Billion | CN¥3.94 Billion | CN¥3.57 Billion | CN¥903.33 Million | ▲ +0.4 pp |
| 2023 | 67.3% | CN¥2.71 Billion | CN¥4.03 Billion | CN¥4.23 Billion | CN¥1.52 Billion | ▼ -6.7 pp |
| 2022 | 74.0% | CN¥3.41 Billion | CN¥4.61 Billion | CN¥4.57 Billion | CN¥1.15 Billion | ▼ -14.8 pp |
| 2021 | 88.8% | CN¥3.66 Billion | CN¥4.13 Billion | CN¥4.05 Billion | CN¥387.26 Million | ▲ +2.0 pp |
| 2020 | 86.8% | CN¥1.16 Billion | CN¥1.33 Billion | CN¥1.40 Billion | CN¥239.23 Million | ▲ +24.8 pp |
| 2019 | 62.0% | CN¥124.09 Million | CN¥200.02 Million | CN¥232.59 Million | CN¥108.49 Million | ▲ +4.5 pp |
| 2018 | 57.6% | CN¥95.61 Million | CN¥166.08 Million | CN¥175.64 Million | CN¥80.02 Million | ▼ -14.2 pp |
| 2017 | 71.7% | CN¥108.19 Million | CN¥150.82 Million | CN¥144.21 Million | CN¥36.02 Million | — |